title: Rapamycin and FK506 induce long-term potentiation by pairing stimulation via an intracellular Ca(2+) signaling mechanism in rat hippocampal CA1 neurons.
abstract: Immunophilin-CsA and -FK506 complexes bind to calcineurin (CaN) and inhibit its phosphatase activity leading to enhancement of neuronal activities. However, inhibition of CaN activity is not the mediator of modulatory activity for IP3 and ryanodine receptors and does not mediate the neurotrophic actions of FK506. FK506 binding protein (FKBP)-12 also binds rapamycin, another immunosuppressant which does not affect CaN activity. Using whole-cell patch clamp techniques, excitatory postsynaptic currents (EPSCs) were recorded and we analyzed the effect of immunosuppressants on the synaptic potentiation induced by pairing weak presynaptic stimulation with postsynaptic depolarization in CA1 neurons of rat hippocampal slices. We found that postsynaptic application of rapamycin or FK506, at low concentrations, but not cyclosporin A, in conjunction with weak pairing stimulation, induced NMDA-dependent long-term potentiation (LTP). The rapamycin-induced LTP was blocked by chelating intracellular Ca(2+) or by inhibiting the intracellular Ca(2+) release. Thus, Ca(2+) release from intracellular Ca(2+) stores is required for the induction of LTP by weak pairing stimulation in the presence of rapamycin or FK506 at postsynaptic sites. We propose that postsynaptic FKBP-12 regulates synaptic transmission by stabilizing the postsynaptic Ca(2+) signaling mechanism in rat hippocampal CA1 neurons.
authors.affiliation: Hyogo Institute for Aging Brain and Cognitive Disorders, 520 Saisho-Ko, 670-0981, Himeji, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Terashima
authors.forename: T
authors.initials: T
authors.lastname: Taniguchi
authors.forename: M
authors.initials: M
authors.lastname: Nakai
authors.forename: M
authors.initials: M
authors.lastname: Yasuda
authors.forename: T
authors.initials: T
authors.lastname: Kawamata
authors.forename: C
authors.initials: C
authors.lastname: Tanaka
mesh_terms: D000818:Animals; D002118:Calcium / Q000378:metabolism; D020013:Calcium Signaling / Q000187:drug effects*; D002614:Chelating Agents / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D004558:Electric Stimulation; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D020104:Immunophilins / Q000737:chemistry; D017774:Long-Term Potentiation / Q000187:drug effects*; D008297:Male; D016202:N-Methylaspartate / Q000502:physiology; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D018408:Patch-Clamp Techniques; D051381:Rats; D017208:Rats, Wistar; D020123:Sirolimus / Q000737:chemistry / Q000494:pharmacology*; D016559:Tacrolimus / Q000737:chemistry / Q000494:pharmacology*; D022021:Tacrolimus Binding Proteins; D013997:Time Factors
chemical_list: D002614:Chelating Agents; D004533:Egtazic Acid; D016202:N-Methylaspartate; D022021:Tacrolimus Binding Proteins; D020104:Immunophilins; C025603:1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; D002118:Calcium; D020123:Sirolimus; D016559:Tacrolimus